Camden Capital, LLC Neurocrine Biosciences Inc Transaction History

Camden Capital, LLC

  • $896 Million
  • Q3 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 05, 2024
BUY
$106.07 - $132.76 $334,120 - $418,194
3,150 New
3,150 $415,000
Q2 2021

Aug 16, 2021
SELL
$89.43 - $102.27 $206,583 - $236,243
-2,310 Closed
0 $0
Q1 2021

May 10, 2021
BUY
$87.57 - $119.4 $202,286 - $275,814
2,310 New
2,310 $225,000

Others Institutions Holding NBIX

# of Institutions
625
Shares Held
94.2M
Call Options Held
632K
Put Options Held
621K
View Full List

About NEUROCRINE BIOSCIENCES INC

NBIX Quotes by TradingView
  • Ticker NBIX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 95,639,296
  • Market Cap $12B
  • Description
  • Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...
More about NBIX
Track This Portfolio

Track Camden Capital, LLC Portfolio

Follow Camden Capital, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Camden Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Camden Capital, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email